<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506881</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-066-1</org_study_id>
    <nct_id>NCT02506881</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers</brief_title>
  <official_title>International Multicenter Comparative Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Safety of BCD-066 and Aranesp® After Single Subcutaneous and Intravenous Injection in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and
      safety of BCD-066 (darbepoetin alfa manufactured by CJSC BIOCAD, Russia) and Aranesp® (Amgen
      Europe B.V., Netherlands) in healthy volunteers. The purpose of the study is to demonstrate
      the equivalence of pharmacokinetics, pharmacodynamics and safety parameters after single
      subcutaneous or intravenous injection. Each drug will be administered to each volunteer at a
      dose of 1 µg per kilogram as a single subcutaneous or intravenous injection with an interval
      of at least 25 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
    <description>Area Under Concentration-time Curve (AUC) of Darbepoetin Alfa From the Moment of Drug Administration Until 336 (sc administration) or 72 (iv administration) Hours and to Infinity(AUC(0-336)/AUC(0-72) and AUC(0-∞) Respectively Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
    <description>Maximal concentration of darbepoetin alfa From the Moment of Drug Administration Until 336 (sc administration) or 72 (iv administration) hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUEC</measure>
    <time_frame>504 hours</time_frame>
    <description>Area Under Effect Curve (AUEC) of reticulocytes count from the Moment of Drug Administration Until 504 hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AC-Emax</measure>
    <time_frame>504 hours</time_frame>
    <description>Maximum elevation of absolute reticulocyte count from the baseline from the Moment of Drug Administration Until 504 hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
    <description>Serum half-life of darbepoetin alfa after single sc of iv administration. Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
    <description>Time to achieve maximum serum concentration of darbepoetin alfa after single sc of iv administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl</measure>
    <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
    <description>Serum clearance of of darbepoetin alfa after single sc of iv administration. Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BCD-066 → Aranesp - subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aranesp → BCD-066 - subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-066 → Aranesp - intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aranesp → BCD-066 - intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <arm_group_label>BCD-066 → Aranesp - subcutaneous</arm_group_label>
    <arm_group_label>Aranesp → BCD-066 - subcutaneous</arm_group_label>
    <arm_group_label>BCD-066 → Aranesp - intravenous</arm_group_label>
    <arm_group_label>Aranesp → BCD-066 - intravenous</arm_group_label>
    <other_name>Aranesp</other_name>
    <other_name>BCD-066</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Male gender

          -  Age 18 - 45 years inclusively

          -  Body mass index (BMI) 19 - 29 kg/m2 inclusively

          -  Hemoglobin level 120-160 g/l (12 - 16 g/dL) inclusively during 14 days prior to first
             study drugs administration

          -  White blood cells count ≥3,0×109/L, Platelet count ≥140×109/L during 14 days prior to
             first study drugs administration

          -  Subjects must be in good health as determined by a medical history, medical
             examination, electrocardiogram, serum biochemistry, haematology, serology and
             urinalysis

          -  Absence of history of systematic alcohol and drug abuse

          -  Ability of the volunteer, in investigator's opinion, to follow the study protocol
             procedures and requirements

          -  Willingness of volunteers and their sexual partners of childbearing potential to use
             reliable contraception methods starting from 2 weeks before inclusion into the study
             and until 4 weeks after receiving the last dose of the investigational products. This
             criterion is not applicable to patients who underwent surgical sterilization. Reliable
             contraceptive measures include one barrier method in combination with one of the
             following methods: spermicides, intrauterine device or oral contraceptives used by
             participant's partner

          -  Consent to avoid alcohol intake within 24 hours before and 48 hours after each
             administration of the test or reference drugs

        Exclusion Criteria:

          -  Clinically significant abnormalities on ECG or in laboratory tests, which could
             interfere with the objective of the study or the safety of the volunteer.

          -  Clinically significant illness within 4 weeks prior to the screening visit

          -  Subjects with past or present history of liver disease, angina, renal disease,
             hypertension, epilepsy, cardiovascular, cerebrovascular, peripheral vascular disease
             or thrombocytosis

          -  History of any oncological disease

          -  Prior exposure to any erythropoietins, darbepoetin

          -  Prior exposure to IV iron supplementation (within 2 years before randomisation)

          -  Subjects who have used any medication, including over-the-counter drugs, herbal
             medications, and nutritional supplements within 14 days prior to IDs administration
             with the exception of paracetamol (acetaminophen) up to 3g per day or ibuprofen up to
             1g per day

          -  Subjects who smoke more than 10 cigarettes per day

          -  Subjects who have donated more than 450 ml of blood within the 1 month prior to ID
             injection

          -  Epileptic seizures within the 6 months prior to ID injection

          -  Major surgery within 1 month prior to the enrollment into the study

          -  Inability to install intravenous catheter (e.g., due to skin disease)

          -  Subjects who have received any experimental drug within 3 months preceding the 1st ID
             administration

          -  Subjects who have a clinically significant history of drug hypersensitivity or
             allergic disease

          -  Possibility that the subject will not cooperate with the requirements of the protocol
             as set out in the volunteer information

          -  Subjects who consume excessive amounts of caffeine (more than 5 cups of coffee per
             day)

          -  Participation in any other clinical study or any preceding participation in other
             studies within 3 months prior to the 1st ID administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Sardaryan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City Mariin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Mariin Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.biocad.ru</url>
    <description>Related info</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <results_first_submitted>March 30, 2016</results_first_submitted>
  <results_first_submitted_qc>March 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2016</results_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>darbepoetin alfa</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-066 → Aranesp - Subcutaneous</title>
          <description>Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
Darbepoetin alfa</description>
        </group>
        <group group_id="P2">
          <title>Aranesp → BCD-066 - Subcutaneous</title>
          <description>Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
Darbepoetin alfa</description>
        </group>
        <group group_id="P3">
          <title>BCD-066 → Aranesp - Intravenous</title>
          <description>Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
Darbepoetin alfa</description>
        </group>
        <group group_id="P4">
          <title>Aranesp → BCD-066 - Intravenous</title>
          <description>Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
Darbepoetin alfa</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of blood storage conditions</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (at Least 25 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population for safety analysis: all patients who received at least one study drug injection</population>
      <group_list>
        <group group_id="B1">
          <title>BCD-066 → Aranesp - Subcutaneous</title>
          <description>Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.</description>
        </group>
        <group group_id="B2">
          <title>Aranesp → BCD-066 - Subcutaneous</title>
          <description>Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.</description>
        </group>
        <group group_id="B3">
          <title>BCD-066 → Aranesp - Intravenous</title>
          <description>Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.</description>
        </group>
        <group group_id="B4">
          <title>Aranesp → BCD-066 - Intravenous</title>
          <description>Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="21" upper_limit="32"/>
                    <measurement group_id="B2" value="22" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="B3" value="24" lower_limit="22" upper_limit="27"/>
                    <measurement group_id="B4" value="24.5" lower_limit="21" upper_limit="28"/>
                    <measurement group_id="B5" value="24" lower_limit="21" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>Area Under Concentration-time Curve (AUC) of Darbepoetin Alfa From the Moment of Drug Administration Until 336 (sc administration) or 72 (iv administration) Hours and to Infinity(AUC(0-336)/AUC(0-72) and AUC(0-∞) Respectively Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
        <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
        <population>Population for pharmacokinetics analysis: patients who received at least one study drug injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066 Subcutaneous</title>
            <description>Pharmacokinetics of darbepoetin alfa after subcutaneous injection of BCD-066 in a dose of 1 µg/kg was analysed.
AUC of darbepoetin alfa 0 to 336 hours is reported.</description>
          </group>
          <group group_id="O2">
            <title>Aranesp® Subcutaneous</title>
            <description>Pharmacokinetics of darbepoetin alfa after subcutaneous injection of Aranesp® in a dose of 1 µg/kg was analysed.
AUC of darbepoetin alfa 0 to 336 hours is reported.</description>
          </group>
          <group group_id="O3">
            <title>BCD-066 - Intravenous</title>
            <description>Pharmacokinetics of darbepoetin alfa after intravenous injection of BCD-066 in a dose of 1 µg/kg was analysed.
AUC of darbepoetin alfa 0 to 72 hours is reported.</description>
          </group>
          <group group_id="O4">
            <title>Aranesp® - Intravenous</title>
            <description>Pharmacokinetics of darbepoetin alfa after intravenous injection of Aranesp® in a dose of 1 µg/kg was analysed.
AUC of darbepoetin alfa 0 to 72 hours is reported.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>Area Under Concentration-time Curve (AUC) of Darbepoetin Alfa From the Moment of Drug Administration Until 336 (sc administration) or 72 (iv administration) Hours and to Infinity(AUC(0-336)/AUC(0-72) and AUC(0-∞) Respectively Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
          <population>Population for pharmacokinetics analysis: patients who received at least one study drug injection.</population>
          <units>(pg/ml)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150607" lower_limit="115435" upper_limit="185031"/>
                    <measurement group_id="O2" value="152208" lower_limit="116362" upper_limit="212041"/>
                    <measurement group_id="O3" value="504584" lower_limit="463396" upper_limit="626538"/>
                    <measurement group_id="O4" value="544818" lower_limit="456106" upper_limit="606407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximal concentration of darbepoetin alfa From the Moment of Drug Administration Until 336 (sc administration) or 72 (iv administration) hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
        <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
        <population>Population for pharmacokinetics analysis included patients who received at least one study drug injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066 Subcutaneous</title>
            <description>Pharmacokinetics of darbepoetin alfa after subcutaneous injection of BCD-066 in a dose of 1 µg/kg was analysed.
Cmax of darbepoetin alfa 0 to 336 hours is reported.</description>
          </group>
          <group group_id="O2">
            <title>Aranesp® Subcutaneous</title>
            <description>Pharmacokinetics of darbepoetin alfa after subcutaneous injection of Aranesp® in a dose of 1 µg/kg was analysed.
Cmax of darbepoetin alfa 0 to 336 hours is reported.</description>
          </group>
          <group group_id="O3">
            <title>BCD-066 - Intravenous</title>
            <description>Pharmacokinetics of darbepoetin alfa after intravenous injection of BCD-066 in a dose of 1 µg/kg was analysed.
Cmax of darbepoetin alfa 0 to 72 hours is reported.</description>
          </group>
          <group group_id="O4">
            <title>Aranesp® - Intravenous</title>
            <description>Pharmacokinetics of darbepoetin alfa after intravenous injection of Aranesp® in a dose of 1 µg/kg was analysed.
Cmax of darbepoetin alfa 0 to 72 hours is reported.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximal concentration of darbepoetin alfa From the Moment of Drug Administration Until 336 (sc administration) or 72 (iv administration) hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
          <population>Population for pharmacokinetics analysis included patients who received at least one study drug injection.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="984" lower_limit="789" upper_limit="1226"/>
                    <measurement group_id="O2" value="885" lower_limit="808" upper_limit="1197"/>
                    <measurement group_id="O3" value="23908" lower_limit="21535" upper_limit="27531"/>
                    <measurement group_id="O4" value="24478" lower_limit="22271" upper_limit="29381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUEC</title>
        <description>Area Under Effect Curve (AUEC) of reticulocytes count from the Moment of Drug Administration Until 504 hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
        <time_frame>504 hours</time_frame>
        <population>Population for pharmacokinetics analysis included patients who received at least one study drug injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066 Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O2">
            <title>Aranesp® Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O3">
            <title>BCD-066 - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O4">
            <title>Aranesp® - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
        </group_list>
        <measure>
          <title>AUEC</title>
          <description>Area Under Effect Curve (AUEC) of reticulocytes count from the Moment of Drug Administration Until 504 hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
          <population>Population for pharmacokinetics analysis included patients who received at least one study drug injection.</population>
          <units>(reticulocytes * 10^9/l)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28248" lower_limit="22162" upper_limit="32648"/>
                    <measurement group_id="O2" value="27916" lower_limit="22827" upper_limit="32628"/>
                    <measurement group_id="O3" value="35610" lower_limit="29578" upper_limit="41423"/>
                    <measurement group_id="O4" value="36928" lower_limit="28773" upper_limit="42247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AC-Emax</title>
        <description>Maximum elevation of absolute reticulocyte count from the baseline from the Moment of Drug Administration Until 504 hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
        <time_frame>504 hours</time_frame>
        <population>Population for analysis of pharmacodynamics included patients who received at least one study drug injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066 Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O2">
            <title>Aranesp® Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O3">
            <title>BCD-066 - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O4">
            <title>Aranesp® - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
        </group_list>
        <measure>
          <title>AC-Emax</title>
          <description>Maximum elevation of absolute reticulocyte count from the baseline from the Moment of Drug Administration Until 504 hours.
Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
          <population>Population for analysis of pharmacodynamics included patients who received at least one study drug injection.</population>
          <units>reticulocytes * 10^9/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" lower_limit="26.8" upper_limit="62.3"/>
                    <measurement group_id="O2" value="54.55" lower_limit="40.7" upper_limit="69.0"/>
                    <measurement group_id="O3" value="71.3" lower_limit="51.9" upper_limit="85.3"/>
                    <measurement group_id="O4" value="72.1" lower_limit="55.5" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2</title>
        <description>Serum half-life of darbepoetin alfa after single sc of iv administration. Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
        <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
        <population>Population for pharmacokinetics analysis: patients who received at least one study drug injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066 Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O2">
            <title>Aranesp® Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O3">
            <title>BCD-066 - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O4">
            <title>Aranesp® - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2</title>
          <description>Serum half-life of darbepoetin alfa after single sc of iv administration. Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
          <population>Population for pharmacokinetics analysis: patients who received at least one study drug injection.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" lower_limit="69.6" upper_limit="92.6"/>
                    <measurement group_id="O2" value="80.6" lower_limit="65.7" upper_limit="89.9"/>
                    <measurement group_id="O3" value="13.1" lower_limit="12.7" upper_limit="13.9"/>
                    <measurement group_id="O4" value="12.7" lower_limit="12.4" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time to achieve maximum serum concentration of darbepoetin alfa after single sc of iv administration</description>
        <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
        <population>Population for pharmacokinetics analysis: patients who received at least one study drug injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066 - Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O2">
            <title>Aranesp® - Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O3">
            <title>BCD-066 - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O4">
            <title>Aranesp® - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to achieve maximum serum concentration of darbepoetin alfa after single sc of iv administration</description>
          <population>Population for pharmacokinetics analysis: patients who received at least one study drug injection.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="16" upper_limit="36"/>
                    <measurement group_id="O2" value="36" lower_limit="36" upper_limit="36"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.08" upper_limit="0.50"/>
                    <measurement group_id="O4" value="0.25" lower_limit="0.08" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cl</title>
        <description>Serum clearance of of darbepoetin alfa after single sc of iv administration. Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
        <time_frame>336 hours (sc) / 72 hours (iv)</time_frame>
        <population>Population for pharmacokinetics analysis: patients who received at least one study drug injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-066 - Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O2">
            <title>Aranesp® - Subcutaneous</title>
            <description>Pharmacodynamics of darbepoetin alfa after subcutaneous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O3">
            <title>BCD-066 - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of BCD-066 in a dose of 1 µg/kg was analysed.</description>
          </group>
          <group group_id="O4">
            <title>Aranesp® - Intravenous</title>
            <description>Pharmacodynamics of darbepoetin alfa after intravenous injection of Aranesp® in a dose of 1 µg/kg was analysed.</description>
          </group>
        </group_list>
        <measure>
          <title>Cl</title>
          <description>Serum clearance of of darbepoetin alfa after single sc of iv administration. Blood samples were taken 30, 20, 10, 0 minutes before injection of study drug and then after 12, 24, 36, 72, 96, 144, 336 and 504 hours post-dose.</description>
          <population>Population for pharmacokinetics analysis: patients who received at least one study drug injection.</population>
          <units>hours*kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.433" lower_limit="0.308" upper_limit="0.587"/>
                    <measurement group_id="O2" value="0.375" lower_limit="0.314" upper_limit="0.566"/>
                    <measurement group_id="O3" value="139.0" lower_limit="123.9" upper_limit="153.7"/>
                    <measurement group_id="O4" value="134.2" lower_limit="114.0" upper_limit="159.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0 to 504 hours after injection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BCD-066 Subcutaneous</title>
          <description>Safety parameters of darbepoetin alfa after subcutaneous injection of BCD-066 in a dose of 1 µg/kg are presented.</description>
        </group>
        <group group_id="E2">
          <title>Aranesp® Subcutaneous</title>
          <description>Safety parameters of darbepoetin alfa after subcutaneous injection of Aranesp® in a dose of 1 µg/kg are presented.</description>
        </group>
        <group group_id="E3">
          <title>BCD-066 - Intravenous</title>
          <description>Safety parameters of darbepoetin alfa after intravenous injection of BCD-066 in a dose of 1 µg/kg are presented.</description>
        </group>
        <group group_id="E4">
          <title>Aranesp® - Intravenous</title>
          <description>Safety parameters of darbepoetin alfa after intravenous injection of Aranesp® in a dose of 1 µg/kg are presented.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Elevated hematocrit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Elevated reticulocyte count</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leucocytosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Decrease in hematocrit</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Decrease in reticulocyte count</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Trombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Monocytosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Elevated neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Elevated basophil count</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Decreased eosinophil count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Increased eosinophil count</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Erythrocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Trombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biryulin Andrey</name_or_title>
      <organization>BIOCAD</organization>
      <phone>+7812380 49 33 ext 925</phone>
      <email>biryulin@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

